Kaplan-Meier analysis of survival of PMF patients stratified according to their driver mutation or a clinical-molecular prognostic model that includes IPSS variables and driver mutation. (A) Patients stratified according to their driver mutation. This analysis illustrates the prognostic significance of the driver mutation: although all patients have a similar PMF phenotype (that is, bone marrow megakaryocytic proliferation with atypia, fibrosis grades 2/3, and abnormal stem cell trafficking), their outcome is largely determined by the driver mutant gene. (B) Patients stratified according to a clinical-molecular prognostic model. As a proof of concept, this analysis illustrates the potential of integrating clinical and molecular data for improving the prognostication precision in clinical practice and in designing clinical trials. The clinical-molecular prognostic model depicted here includes JAK2, CALR, and MPL mutation status in addition to the IPSS variables. Modified from Rumi et al⁸⁵  with permission.